TScan Therapeutics Inc. (TCRX) and the Battle of Fundamentals vs. Technicals – News Heater
Home  »  Hot Stocks   »  TScan Therapeutics Inc. (TCRX) and the Battle of F...

TScan Therapeutics Inc. (TCRX) and the Battle of Fundamentals vs. Technicals

TScan Therapeutics Inc. (NASDAQ:TCRX) went up by 20.61% from its latest closing price compared to the recent 1-year high of $14.71. The company’s stock price has collected -1.00% of loss in the last five trading sessions.

Is It Worth Investing in TScan Therapeutics Inc. (NASDAQ :TCRX) Right Now?

Opinions of the stock are interesting as 4 analysts out of 5 who provided ratings for TScan Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


The average price from analysts is $14.00, which is $13.51 above the current price. TCRX currently public float of 13.62M and currently shorts hold a 0.16% ratio of that float. Today, the average trading volume of TCRX was 57.75K shares.

TCRX’s Market Performance

TCRX stocks went down by -1.00% for the week, with a monthly drop of -13.48% and a quarterly performance of -61.58%. The volatility ratio for the week stands at 17.21% while the volatility levels for the past 30 days are set at 10.29% for TScan Therapeutics Inc.. The simple moving average for the period of the last 20 days is -12.81% for TCRX stocks with a simple moving average of -67.69% for the last 200 days.

TCRX Trading at -32.30% from the 50-Day Moving Average

After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.47% of loss for the given period.

Volatility was left at 10.29%, however, over the last 30 days, the volatility rate increased by 17.21%, as shares sank -26.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.62% lower at present.

During the last 5 trading sessions, TCRX fell by -1.00%, which changed the moving average for the period of 200-days by -79.29% in comparison to the 20-day moving average, which settled at $2.2465. In addition, TScan Therapeutics Inc. saw -55.78% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TCRX starting from Silver Brian M., who purchase 15,000 shares at the price of $3.40 back on Mar 24. After this action, Silver Brian M. now owns 26,885 shares of TScan Therapeutics Inc., valued at $50,982 using the latest closing price.

ZDRAVESKI ZORAN, the Chief Legal Officer of TScan Therapeutics Inc., purchase 4,716 shares at $7.48 during a trade that took place back on Sep 23, which means that ZDRAVESKI ZORAN is holding 4,716 shares at $35,255 based on the most recent closing price.

Stock Fundamentals for TCRX

Current profitability levels for the company are sitting at:

  • -479.65 for the present operating margin
  • +67.18 for the gross margin

The net margin for TScan Therapeutics Inc. stands at -479.49. Equity return is now at value -86.50, with -29.30 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 7.76.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam